Expression of Proto-Oncogene cFMS Protein in Lung, Breast, and Ovarian Cancers

Abstract

We performed immunohistochemistry for macrophage colony-stimulating factor 1 receptor (also known as c-fms proto-oncogene product) on tissue microarrays of human nontumor lung, pulmonary squamous cell carcinomas (SCC) and adenocarcinomas (ADC), and breast and ovarian carcinomas using a commercially available anti-cFMS antibody. The specificity of the antibody was validated by Western blot and mass spectrometry analysis. Staining of cFMS was restricted to stromal fibroblasts in pulmonary SCC and ADC specimens and was not identified in tumor epithelium or epithelium and stromal cells of nontumor lung. Evaluation of pulmonary SCC (n=63) and ADC (n=71) specimens revealed stromal fibroblast cFMS staining in 60% (38 of 63) and 35% (25 of 71) of the tumor samples, respectively. A similar pattern of stromal fibroblast cFMS staining was observed in breast (n=21) and ovarian (n=50) carcinomas. It was reported that glucocorticoids induced cFMS expression in breast carcinomas and choriocarcinomas. To investigate whether stromal cFMS expression in lung cancers was associated with glucocorticoid signaling, glucocorticoid receptor protein distribution was evaluated in lung tissue microarrays by immunohistochemistry. Stromal fibroblast glucocorticoid receptor staining was only observed in 18% (2 of 11) of pulmonary SCC and 6% (1 of 17) of ADC specimens, suggesting that cFMS expression may not be directly mediated by glucocorticoids in stromal fibroblasts of lung cancers. The tumor stromal cell expression of cFMS in certain tumor types (lung, ovarian, and breast) suggests the potential for more diverse tumor therapeutic options and presents an attractive target for drug development.

The Antimetastatic and Antiangiogenesis Effects of Kefir Water on Murine Breast Cancer Cells

“… 47 G-CSF was identified as a macrophage regulator to promote proliferation, differentiation, and survival. 48 However, G-CSF along with GM-CSF can also act as proto-oncogenes, in which they are highly expressed in various tumors 49 - 51 and also frequently found in invasive breast cancer cells. 52 They were also found in abundance in the cytokine profile of metastatic 4T1 tumors.…”

In Vivo Assessment of Ovarian Tumor Response to Tyrosine Kinase Inhibitor Pazopanib by Using Hyperpolarized13C-Pyruvate MR Spectroscopy and18F-FDG PET/CT Imaging in a Mouse Model

“…Ravoori et al cFms (25), and fibroblast growth factor receptor (26,27) are not noted to be essential drivers of ovarian cancer cells. Platelet-derived growth factor receptor-a inhibition does not inhibit SKOV3 cell proliferation (28).…”

Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis

“…Anlotinib is a novel oral multi-targeted receptor tyrosine kinase inhibitor (TKI), which can effectively inhibit VEGFR, PDGFR, FGFR, C-KIT and other kinases, and has anti-tumor angiogenesis and anti-tumor growth effects [ 5 – 8 ]. Results from a number of previous phase II and III clinical trials have shown that amlotinib exhibits good antitumor activity in a variety of solid tumors, including non-small-cell lung cancer, renal carcinoma, gastric cancer, hepatocarcinoma and soft tissue sarcoma [ 9 ].…”